Quick Answer
Royalty Pharma plc reported Total Assets of $19.62 billion for fiscal year 2025.
Royalty Pharma plc Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $19.62B | +7.7% |
| 2024 | $18.22B | +11.2% |
| 2023 | $16.38B | -2.6% |
| 2022 | $16.81B | -4.0% |
| 2021 | $17.52B | +9.3% |
| 2020 | $16.02B | +28.7% |
| 2019 | $12.45B | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $19.35B | +7.2% | +5.6% |
| June 30, 2025 | $18.32B | +3.8% | +4.1% |
| March 31, 2025 | $17.61B | +9.2% | -3.4% |
| December 31, 2024 | $18.22B | +11.2% | +1.0% |
| September 30, 2024 | $18.04B | +13.8% | +2.2% |
| June 30, 2024 | $17.66B | +3.1% | +9.5% |
| March 31, 2024 | $16.13B | -5.5% | -1.5% |
| December 31, 2023 | $16.38B | -2.6% | +3.3% |
- Royalty Pharma plc showed an increase of +7.7% in Total Assets compared to the prior fiscal year.
- Over the 2019–2025 period, Royalty Pharma plc’s total assets has grown by 57.6% (from $12.45 billion to $19.62 billion).
- The most recent figure is from Royalty Pharma plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: